Objectives

After participating in this educational activity, attendees should be able to:
1. Define distinguishing characteristics of argatroban use in heparin induced thrombocytopenia (HIT).
2. Describe the process of transitioning a patient from argatroban to warfarin
3. Analyze the transition from argatroban to warfarin through a patient case

Faculty

Christina Lombardi, PharmD

PGY1 Pharmacy Resident

Pharmacist
Baystate Medical Center 

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.